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RESUMO
Introdução: A polimedicação é observada nos doentes idosos e está associada a um maior risco de reações adversas, efeitos 
secundários e interações. Os clínicos devem atentos à prescrição inapropriada e à redução da polimedicação.
Material e Métodos: Estudo observacional, longitudinal, retrospetivo e descritivo, realizado numa enfermaria de medicina interna num 
hospital português. Definimos a polimedicação como o uso de cinco ou mais medicamentos. O objetivo foi descrever a prevalência da 
polimedicação e a prescrição inapropriada, na admissão e alta, de acordo com as guidelines/algoritmos definidos em deprescribing.
org. Admitimos 838 doentes entre janeiro e julho de 2017. Excluímos todos aqueles com idade inferior a 65 anos e óbitos. A medicação 
dos doentes foi revista a partir da base de dados hospitalar, à admissão e à data de alta. Examinámos se os doentes estavam a tomar 
anticoagulantes, inibidores da bomba de protões, benzodiazepinas, antipsicóticos e/ou anti hiperglicémicos.
Resultados: Incluímos 483 doentes, com média de idade de 79,2 ± 8,0 anos, e 42% dos quais eram homens. A mediana da medicação 
à admissão e à alta foi seis. A polimedicação estava presente em mais de 70% dos doentes admitidos. Os inibidores da bomba de 
protões foram a classe mais inapropriadamente prescrita à data de alta (17,2%). 
Discussão: Demonstrámos um uso reduzido de fármacos inapropriados (11,2% - 17,2%) nos idosos, à alta hospitalar, quando 
comparado com outros estudos. 
Conclusão: Demonstrámos que a polimedicação estava presente em mais de 70% dos idosos admitidos. Contudo, a taxa de 
prescrição inapropriada não afetou significativamente a polimedicação na admissão e na alta, sendo inferior aos dados publicados.  
Palavras-chave: Desprescrições; Idoso; Polimedicação; Portugal; Prescrição Inadequada
Inappropriate Prescribing to Elderly Patients in an Internal 
Medicine Ward 
Prescrição Inapropriada em Idosos numa Enfermaria de 
Medicina Interna
1. Departamento de Medicina Interna. Hospital Professor Doutor Fernando Fonseca. Amadora. Portugal.
2. Departamento de Cardiologia. Hospital Professor Doutor Fernando Fonseca. Amadora. Portugal.
 Autor correspondente: Joana Urzal. joana.urzal@hff.min-saude.pt
Recebido: 17 de abril de 2018 - Aceite: 28 de agosto de 2018 | Copyright © Ordem dos Médicos 2019
Joana URZAL1, Ana Bárbara PEDRO1, Inês Ferraz de OLIVEIRA1, Inês ROMERO1, Miguel ACHEGA1, Iuri CORREIA1, 
Fernando ALDOMIRO1, João AUGUSTO2
Acta Med Port 2019 Feb;32(2):141-148  ▪  https://doi.org/10.20344/amp.10683
ABSTRACT
Introduction: Polypharmacy is often observed in elderly patients and is associated with an increased risk of adverse drug reactions, 
side effects and interactions. Clinicians should be alert to inappropriate drug prescribing and reduce polypharmacy. 
Material and Methods: Observational, longitudinal, retrospective and descriptive study in an internal medicine ward in a Portuguese 
hospital. Polypharmacy was defined as the use of five or more different medicines. The purpose of this study was to describe the 
prevalence of polypharmacy and inappropriate prescribing at admission and discharge in an internal medicine ward, according to 
deprescribing.org guidelines/algorithms. A total of 838 consecutive patients were admitted between January and July 2017. All patients 
were aged under 65 years old, and those who died before discharge were excluded. Patients’ medications were reviewed from a 
medical database at hospital admission and discharge. We examined whether patients were taking anticoagulants, proton pump 
inhibitors, benzodiazepines, antipsychotics and/or antihyperglycemic medication.
Results: A total of 483 patients were included, mean age was 79.2 ± 8.0 years, and 42% of patients were male. Median number of 
medications at admission and discharge was six. Polypharmacy was present in more than 70% of admitted patients. Proton pump 
inhibitors were the most common inappropriate prescription at discharge (17.2%). 
Discussion: This study demonstrated a low use of inappropriate medicine (11.2% - 17.2%) in older people discharged from hospital, 
when compared to other studies. 
Conclusion: Our study shows that polypharmacy is present in more than 70% of elderly admitted patients. Nevertheless, the drug 
inappropriateness rate was not significantly affected by polypharmacy at both admission and discharge, being overall lower than 
published data. 
Keywords: Aged; Deprescriptions; Inappropriate Prescribing; Polypharmacy; Portugal
INTRODUCTION
 Mean life expectancy is increasing worldwide due to 
scientific developments and better disease prevention and 
treatment. Portugal is currently the fifth leading country 
in Europe in terms of life expectancy, with a 2016 regis-
tered ageing index of 148.7%.1 Older people develop more 
chronic conditions such as arterial hypertension (HTN), car-
diac failure, diabetes, dyslipidemia, renal failure, sleeping 
disorders, neurologic diseases and cancer. Consequently, 
elderly people require multiple medications.2,3 
 The term polypharmacy comes from two Greek root 
words: poly, meaning many, and pharmakeia meaning 
medicines or drugs. Polypharmacy is defined by the World 
Health Organization as “the administration of many drugs at 
the same time or the administration of an excessive number 
of drugs”.4 This definition is not clear as it does not refer 
to a specific number, neither indicates the temporal condi-
tion under which polypharmacy is administered simultane-
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threshold defining polypharmacy.6,7 Therefore, in this study 
we defined polypharmacy if a patient was taking five or 
more medications, in order to compare with other studies. 
The notion of polypharmacy is often confused with inappro-
priate prescription.8 
 Potentially inappropriate medications (PIMs) are de-
fined as drugs with ineffectiveness or high risk–benefit ratio. 
However, the high prevalence of PIMs should not be only 
attributed to inappropriate prescribing.9,10 Use of PIMs has 
been correlated with worse outcomes for the patient, in-
cluding an increased risk of adverse drug reactions (ADRs), 
side effects, interactions, hospitalisation and mortality.11 
ADRs can cause confusion, delirium, falls, hip fractures 
and a significant proportion of potential emergency room 
visits and hospitalisations, which could be avoided.12 The 
elderly population, due to their age and chronic conditions, 
may respond differently to drug or experience more severe 
ADRs.13 This can be explained by different pharmacokinetic 
and pharmacodynamic characteristics that take place later 
in life and can significantly contribute to enhanced drug re-
lated morbidity and mortality.14 
 Polypharmacy might be a serious public health problem 
concerning medicine’s direct and indirect costs from drug-
related morbidity.15 Rational drug discontinuation in older 
adults is a logical approach to mitigate polypharmacy. 
 Deprescribing is an active review process that prompts 
the physician to consider which medications have lost their 
advantage in the risk–benefit trade-off, especially in patients 
with changing goals of care or limited life expectancy.16 
 There is a lack of data regarding the prevalence of poly-
pharmacy in people over 65 years old in Portugal. There 
are some studies referring a polypharmacy prevalence of 
18.8%,17 63.3%,18 64.8%19 in a same day center, in two 
healthcare centers and 4th National Health Survey, respec-
tively. The prevalence of polypharmacy in the elderly popu-
lation in other countries varies widely, ranging from 21% in 
Australia,20 40% in Sweden,21 63% in Canada,22 to 86% in 
Korea.23
 There are plenty of tools to help with medication review 
and deprescribing such as the Beers criteria,24,25 START 
(screening tool to alert doctors to the right treatment),26 
STOPP,27 ARMOR (assess, review, minimize, optimize, 
reassess),28 ARS (anticholinergic risk scale), geriatric-pal-
liative method, prescribing optimization method,29 and oth-
ers. Nevertheless, these tools do not provide guidance or a 
practical approach to apply in daily clinical practice.
 The Portuguese public health authority (Direção Geral 
da Saúde) has recently issued a recommendation concern-
ing drug reconciliation.30 Despite these recommendations 
and tools, there are no guidelines in Portugal or Europe on 
how clinicians should deprescribe in elderly patients. The 
Canadian organization Bruyère Research Institute (depre-
scribing.org) and the Institut Universitaire de Gériatrie de 
Montréal (Centre de Reserche), provide guidelines and al-
gorithms for deprescribing proton pump inhibitors (PPI),31,32 
antihyperglycemic agents (AH),33,34 antipsychotics (AP)35,36 
and benzodiazepines (BZ),37,38 that can easily be applied to 
daily clinical practice. 
 The aim of this study was to describe the prevalence of 
polypharmacy and inappropriate prescribing at admission 
and discharge in an internal medicine ward, according to 
deprescribing.org guidelines/algorithms.
MATERIAL AND METHODS
Study design and population
 This is an observational, longitudinal, retrospective 
and descriptive study based on the population of an Inter-
nal Medicine ward in Hospital Fernando Fonseca (HFF), a 
public hospital in a Portuguese urban centre (population 
600 000). 
 We used a convenience sample of patients aged 65 
years or older who were discharged from an Internal Medi-
cine ward, between January 1st, 2017, and July 31st, 2017. 
Exclusion criteria included patients whose electronic charts 
were incomplete or unavailable, and patients who died be-
fore discharge.
Data collection
 We collected demographic and clinical data from elec-
tronic charts regarding all patients involved. We considered 
the following age range for data analysis: [65 - 75], [76 - 85] 
and ≥ 86 years old. Clinical variables included information 
on Barthel Index (BI), comorbidities, drugs, length of stay 
and readmission within 30 days after discharge (no matter 
the cause).
 BI is an ordinal scale used to measure performance in 
daily living activities and it is validated to the Portuguese 
population.39 The patients’ BI ratings were calculated ac-
cording to information on nursing notes and records at hos-
pital admission. Total possible scores range from 0 - 100. 
A patient with a score under 20 is totally dependent, for a 
score between 20 - 39 is very dependent, 40 - 59 is partially 
dependent, 60 - 79 is minimally dependent and if it is 80 - 
100 the patient is independent.
 Polypharmacy was defined as a use of five or more dif-
ferent medicines.
 From the 15 most common chronic diseases,40 we eval-
uated data records regarding 6 that have major impact on 
life expectancy: hypertension (HTN), type 2 diabetes melli-
tus, cancer, chronic obstructive pulmonary disease (COPD), 
chronic kidney disease (CKD) and dementia.
 We reviewed patients’ medications from a medical da-
tabase at hospital admission and at discharge according to 
deprescribing.org guidelines/algorithms of PPI, BZ, AP and 
AH. We examined if patients were taking any anticoagulant 
(AC), PPI, BZ, AP and AH. 
Outcomes
 Primary outcome was defined as the prevalence of poly-
pharmacy and inappropriate prescription at admission and 
discharge on this sample, according to deprescribing.org 
guidelines/algorithms.
 Secondary outcomes were readmission rates within 30 
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Statistical analysis
 Discrete variables are presented as absolute frequen-
cies with percentages, and continuous variables as mean 
± standard deviation if normally distributed, otherwise as 
median with interquartile range (IQR). Data was checked 
for normal distribution using Kolmogorov–Smirnov test.
 Baseline characteristics of patients were compared us-
ing Fisher’s exact test for categorical variables; parametric 
data was compared using Students’ t-test; nonparametric 
data were evaluated using Mann-Whitney U test.
 Differences in the proportions of polypharmacy therapy 
at admission and at discharge were assessed using a two-
related groups McNemar test.
 All statistical analyses were performed using version 
22.0 of SPSS for Windows® (SPSS Inc., Chicago, IL, USA). 
All tests were bilateral and with a level of significance of 5%.
RESULTS
Study sample
 A total of 838 patients were initially evaluated in the in-
ternal medicine ward between January and July 2017. All 
patients were aged under 65 years old, and those who died 
during their stay in hospital, were excluded. A total of 483 
patients were included in our final analysis (Fig. 1).
 Mean age was 79.2 ± 8.0 years, and 42% of the patients 
were male. 
 Median length of stay was 11.3 (7.5 - 16.9) days, with 
a maximum hospitalisation of 67 days. Overall, 48% of our 
patients had HTN, 26% had dementia, 24% type 2 diabetes 
mellitus, 14% COPD, 12% cancer and CKD was present in 
12% of our patients. Patients included in this study had a 
Barthel index median of 65. 
 Clinical and demographic characteristics are presented 
in Table 1.
Drug use and polypharmacy
 The median number of medicines (among all taken 
drugs) at admission and at discharge was similar, 6 [4 - 8]. 
There were no significant differences in the proportion of 
patients under polypharmacy therapy at admission (n = 
361; 74.7%) and at discharge (n = 339; 70.2%), p = 0.084. 
At both admission and discharge, polypharmacy was not 
significantly associated with age (p = 0.689 and p = 0.670, 
respectively) or sex (p = 0.596 and p = 1.000, respectively).
In this study, PPI was the most prescribed drug (36%), fol-
lowed by AH (17%), AP (15.9%) and BZD (14.6%).
 Overall, polypharmacy was mainly driven by BZD, PPI 
and AH both at hospital admission and time of discharge 
(Table 1), with PPI being the most commonly prescribed 
drug in both instances.
 Patients with polypharmacy at admission presented 
more frequently HTN (51.8% vs 37.7%; p = 0.009), type 
2 diabetes mellitus (28.8% vs 11.5%; p < 0.001), COPD 
(16.3% vs 6.6%; p = 0.006), and CKD (14.1% vs 4.1%; p 
= 0.002). On the other hand, patients with polypharmacy at 
discharge exhibited more frequently HTN (55.2% vs 31.9%; 
p ≤ 0.001) and COPD (15.9% vs 9.0%; p = 0.045). Interest-
ingly, dementia did not significantly affect the decision to 
use anticoagulants or not (9.5% of patients with dementia 
were taking anticoagulants versus 11.5%; p = 0.621).
 Patients with polypharmacy at both admission and dis-
charge did not have a significantly lower Barthel score in 
comparison with patients without polypharmacy (at admis-
sion, median score of 65 in patients with polypharmacy 
versus 55 without polypharmacy with p = 0.745 and at dis-
charge, median score of 60 in patients with polypharmacy 
versus 65 without polypharmacy with p = 0.623).
Inappropriate prescription
 The proportion of inappropriate prescription at discharge 
varied between 11.2% and 17.2%, being higher for PPI and 
lower for BZD. AH represented 12% of inappropriate pre-
scription at discharge and AP 13.5%.
 Unexpectedly, polypharmacy at admission and dis-
charge did not significantly affect drug inappropriateness 
rate (Table 2).
Patients´ outcomes
 At admission, there were no significant differences in 
length of hospital stay between patients who had polyphar-
macy (11.3 days) and those who did not have polypharmacy 
(11.5 days), with a p value of 0.614 (Fig. 2). 
Figure 1 – Study population
Admitted internal medicine 
ward
n = 838
Included in our study
n = 483
Excluded patients under 65 
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 At discharge, there were no significant differences in 
length of hospital stay between patients who had polyphar-
macy (11.3 days) and those who did not have polypharmacy 
(11.5 days), with a p-value of 0.345 (Fig. 3).
 Total 30-day readmission rates were low, 2.5% (n = 12). 
There were no significant differences in 30-day readmission 
rates in patients with polypharmacy versus no polypharma-
cy at admission (2.8% vs 1.6%, respectively; p = 0.739) or 
at discharge (2.9% vs 1.4%, respectively; p = 0.523).
DISCUSSION
 There seems to be a slight decrease in polypharmacy, 
after the age of 85, which corresponds to less than a quarter 
of this population. We believe this happens because there 
is a delay in the perception of need for deprescribing until 
patients get very old. However, in our study, polypharmacy 
was not significantly associated with age at admission and 
discharge, (p = 0.689 and p = 0.670, respectively). 
 In this study, polypharmacy was similar to what has been 
previously described in other studies41 focusing on patients’ 
use of medicines on hospital admission and discharge.
 In our study, PPI was the most prescribed drug, as seen 
in other studies.42,43 PPI is often considered a safe and well 
tolerated drug, although it is not as innocuous as many phy-
sicians believe. If PPI is inappropriately prescribed or used 
for a long time, it can contribute to polypharmacy and other 




p value < 5 drugs  ≥ 5 drugs < 5 drugs  ≥ 5 drugs
n (%) 122 (25.3) 361 (74.7) 144 (29.8) 339 (70.2)
Age (years) (mean ± SD) 79.0 ± 8.6 79.3 ± 7.8 0.689 79.4 ± 8.4 79.1 ± 7.8 0.670
  65 - 75, n (%) 43 (35.2) 116 (32.1) 0.578 50 (34.7) 109 (32.2) 0.598
  76 - 85, n (%) 44 (36.1) 156 (43.2) 0.169 52 (36.1) 148 (43.7) 0.131
  ≥ 86, n (%) 32 (26.2) 87 (24.1) 0.629 41 (28.5) 78 (23.0) 0.206
Sex     
  Male, n (%) 54 (44.3) 149 (41.3)
0.596
60 (41.7) 143 (42.2)
1.000
85 (58.3) 196 (57.8)  Female, n (%) 68 (55.7) 212 (58.7)
Chronic conditions     
  Hypertension, n (%) 46 (37.7) 187 (51.8) 0.009 46 (31.9) 187 (55.2) < 0.001
  Dementia, n (%) 27 (22.1) 99 (27.4) 0.284 32 (22.2) 94 (27.7) 0.215
  Diabetes mellitus, n (%) 14 (11.5) 104 (28.8) < 0.001 27 (18.8) 91 (26.8) 0.064
  Chronic obstructive pulmonary disease, n (%) 8 (6.6) 59 (16.3) 0.006 13 (9.0) 54 (15.9) 0.045
  Cancer, n (%) 18 (14.8) 41 (11.4) 0.339 19 (13.2) 40 (11.8) 0.652
  Chronic kidney disease, n (%) 5 (4.1) 51 (14.1) 0.002 12 (8.3) 44 (13.0) 0.164
     Stage II, n (%) 1 (0.8) 13 (3.6) 0.207 4 (2.8) 10 (2.9) 1.000
     Stage III, n (%) 2 (1.6) 29 (8.0) 0.010 7 (4.9) 24 (7.1) 0.423
     Stage IV, n (%) 2 (1.6) 8 (2.2) 1.000 1 (0.7) 9 (2.7) 0.294
     Stage V, n (%) 0 1 (0.3) 1.000 0 1 (0.3) 1.000
Barthel index, median (IQR) 55 (10 - 100) 65 (20 - 95) 0.745 65 (10 - 100) 60 (20 - 85) 0.623
Medication     
  Anticoagulants, n (%) 9 (7.4) 44 (12.2) 0.180 13 (9.0) 40 (11.8) 0.429
  BZD, n (%) 8 (6.6) 63 (17.5) 0.003 9 (6.3) 62 (18.3) < 0.001
  PPI, n (%) 33 (27.0) 141 (39.1) 0.017 29 (20.1) 145 (42.8) < 0.001
  AH, n (%) 12 (9.8) 68 (18.8) 0.024 12 (8.3) 68 (20.1) 0.001
  AP, n (%) 19 (15.6) 58 (16.1) 1.000 16 (11.1) 61 (18.0) 0.077
Independent samples Student’s t-test was used to assess differences between normally distributed variables, whereas Mann-Whitney U-test was used to evaluate differences between 
non-parametric variables. Fisher´s exact test was used to assess differences between discrete variables.
AH: antihyperglycemic; AP: antipsychotic; BZD: benzodiazepine; IQR: interquartile range; PPI: proton pump inhibitor; SD: standard deviation





 < 5 drugs  ≥ 5 drugs < 5 drugs  ≥ 5 drugs
Overall drug inappropriateness, n (%)* 27 (22.1) 99 (27.4) 0.284 32 (22.2) 94 (27.7) 0.215
* Overall drug inappropriateness defined as inappropriateness for at least one drug.
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issues such as aspiration pneumonia44 and dementia.45 
 The most prescribed PIM at hospital discharge was PPI, 
the least prescribed PIM was BZD, which is similar to other 
studies.46-48 
 In this study, AH treatment was prescribed in 80 (17%) 
patients, and polypharmacy was present in 72% and 76% 
patients in hospital admission and discharge, respectively. 
This finding was similar to other studies.49,50 In 19 patients, 
there was no risk of hypoglycemia. However, we found it 
was present in 61 patients who were at risk, or potential 
risk, of hypoglycemia: 20 patients were taking insulin ther-
apy (biphasic isophane insulin), 12 were taking sulphonylu-
reas (gliclazide), 10 had dementia, eight had CKD, six had 
possible drug interaction (corticosteroids in five patients and 
hydrochlorothiazide in one patient) and 10 had low average 
life expectancy and frailty risk. Physicians should set indi-
vidualized A1C and blood glucose targets to decrease drug 
related hypoglycemia risk. In older age, frailty, and multiple 
comorbidities patients, A1C under 8.5% and blood glucose 
under 216 mg/dL may be acceptable.51
 AP prescription was higher than expected according to 
other studies,52 probably because of bias on data collection 
due to incomplete patient records. BZD prescription was 
similar to other studies.53
 In comparison to other studies, BI was higher in this 
study, meaning patients had a greater level of autonomy.54 
However, patients with polypharmacy at admission or dis-
charge did not have a significantly lower BI, in comparison 
with patients without polypharmacy (at admission, median 
score of 65 in patients with polypharmacy versus 55 with-
out polypharmacy with p = 0.745 and at discharge, median 
score of 60 in patients with polypharmacy versus 65 without 
polypharmacy with p = 0.623 - Table 1). Results show that 
polypharmacy is linked to comorbidities but not to lower au-
tonomy (as inferred from BI). The higher BI is often related 
to shorter length of stay and polypharmacy side effects may 
only be present in the ambulatory setting. Given that our pa-
tients were less dependent than those who were included in 
other studies, we may conclude that deprescription is also 
delayed because of a false perception of less frailty.
 Our study demonstrates a lower usage of inappropriate 
medications in older people discharged from an acute care 
hospital when compared to published data,55 although the 
criteria used to judge the appropriateness of prescribing 
were different. 
 Other studies, also regarding the elderly, show a very 
low prevalence (16% and 25.5%) of inappropriate prescrib-
ing in tertiary health care settings,56,57 21.4% in primary 
care,58 51.3% in acute hospital setting (Europe),41 66% in 
a geriatric hospital55 and a higher prevalence (82.6%) was 
Figure 2 – Length of hospital stay (in days) according to polypharmacy at admission: in patients who did not have polypharmacy length 
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observed in a nursing care home.59 
 There were no significant differences in length of hospi-
tal stay between patients who had polypharmacy and those 
who did not have polypharmacy, at both admission and dis-
charge, which is not consistent with other studies.60 
 Older adults that use higher numbers of medicines, 
have increased adverse drug events and increased risk of 
adverse health outcomes. Decreasing polypharmacy and 
avoiding inappropriate prescribing therefore constitutes a 
major goal of care in this population. Clinicians should have 
an organized approach to systematically review the pa-
tient’s therapeutic chart and eliminate unnecessary agents. 
They should explain to patients and their families why a 
given medicine may no longer be essential or beneficial 
according to the present clinical condition. The decision to 
maintain, reduce or discontinue a drug is based on a bal-
ance between its indication and effectiveness and possible 
harms of use, including actual or potential side effects, drug 
interactions, pill burden, and costs.
 Admission in an internal medicine ward is an important 
moment to involve physicians, nurses and pharmacist in or-
der to detect if there is any inappropriate prescribing and 
decrease drug related morbidity. 
 The present study is retrospective and data collection 
can cause bias due to the possibility of incomplete patient 
records. Drug dosage, regime undertaken and other comor-
bidities/drugs that weren’t registered, could interact with the 
medicines evaluated. Presence of comorbidities was only 
ascertained during hospital stay; as such, eventual impact 
of new diagnoses or previous incorrect diagnoses were not 
taken into consideration in our analysis.
CONCLUSION
 Polypharmacy is an important public health problem 
worldwide.
 Decreasing polypharmacy and avoiding inappropriate 
medicines is a common goal of care in elderly people. Mul-
tidisciplinary team effort to do a regular prescription recon-
ciliation and review is the golden rule to identify and reduce 
drug-related problems. There are tools to help the clinician 
improve prescribing and decrease high-risk/low-benefit 
medicines usage. However, a national guideline for depre-
scribing in Portugal is yet to be made. Future research is 
needed, focused on clinical, humanistic, and economic ef-
fect of deprescribing in the geriatric population.
 Our study showed that polypharmacy is present in more 
than 70% of admitted elderly patients. Deprescribing is 
probably not a major concern for physicians yet, given the 
number of medications that remains unchanged between 
admission and discharge. Nevertheless, polypharmacy 
Figure 3 – Length of hospital stay (in days) according to polypharmacy at discharge: in patients who did not have polypharmacy length 
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did not significantly affect the drug inappropriateness rate. 
PPI was the most common inappropriate drug at discharge 
(17.2%), matching worldwide data.
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